Sorry!! The article you are trying to read is not available now.
Vertex Pharmaceuticals Shares Drop on Disappointing Sales, Quarterly Loss
MINYANVILLE ORIGINAL Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) are dropping after the company reported disappointing sales results for its hepatitis C and cystic fibrosis treatments. Announcing that it lost $57.5 million in the third quarter Vertex said it booked $254 million in revenue from hepatitis drug Incivek and $49 million from its cystic fibrosis treatment Kalydeco. Sales of both drugs which make up all of Vertex’s product revenue fell short of Wall Street analysts’ expectations. The company did reiterate an estimate that Incivek sales would be as much as $1.25 billion this year. The drug was approved in May of ...
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here